After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody–drug conjugate can be given as a single agent or in combination with chemotherapy.

中文翻译：

---

Gemtuzumab Ozogamicin卷土重来

吉妥单抗ozogamicin在7年前被撤出市场后，已获得FDA的重新批准，这次是针对新诊断为急性髓性白血病的成年人以及2岁及以上复发/难治性疾病的患者。靶向CD33的抗体-药物偶联物可以单药或与化学疗法联用。